Goebel is a professor of computing science at the University of Alberta and is involved in academic and industrial projects in Europe and Japan. His appointment is aimed at further advancing the the company's predictive-analytics tools and insights capabilities.
There is a lack of medical cannabis data, according to the company, which is aiming to be a front-runner in filling demand.
CB2 Insights currently evaluates 65,000 patients annually through its clinic network and handles millions of clinically validated data points to advance understanding of the effectiveness and risks associated with cannabinoid therapy.
"There is no question that there is an urgent need for more robust usable data systems within the medical cannabis space," said Dr. Goebel. "I am excited to help CB2 Insights advance its platform to better exploit the critical data it ingests every day and explore cannabinoid therapy in a way that has not previously been done."
Dr. Goebel will help work on platform architecture and design enhancements to help serve a variety of new stakeholders in the company such as regulatory bodies, government agencies, researchers and pharma firms.
Meanwhile, on Wednesday, in a separate statement, the company announced it had completed the conversion of 100% of outstanding convertible senior secured debentures entered into between May and September 2017, retiring $959,000 of principal, accrued interest and outstanding fees by issuing more than 7.5 million common shares
Contact Giles at [email protected]
Follow him on Twitter @Gile74